Cartesian Therapeutics, Inc. — Director's Dealing 2026

Jan 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2026-01-02

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-02	Common Stock	A	2600	—	Acquired	8646285	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-02	Stock Option (Right to Buy)	$6.76	A	7800	Acquired	2036-01-01	Common Stock (7800)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	330695	Indirect
Common Stock	656513	Indirect

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.